Praxis Precision Medicines (NASDAQ:PRAX) Now Covered by B. Riley Financial

Investment analysts at B. Riley Financial assumed coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) in a report released on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $713.00 price target on the stock. B. Riley Financial‘s price objective suggests a potential upside of 129.33% from the company’s previous close.

Several other analysts also recently commented on PRAX. JPMorgan Chase & Co. began coverage on Praxis Precision Medicines in a research note on Friday, October 16th. They set an “overweight” rating and a $700.00 target price on the stock. Guggenheim raised their price objective on Praxis Precision Medicines from $800.00 to $1,050.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright restated a “buy” rating on shares of Praxis Precision Medicines in a research note on Wednesday, November 11th. Wedbush raised their price target on shares of Praxis Precision Medicines from $188.00 to $189.00 and gave the company an “underperform” rating in a research report on Tuesday, November 10th. Finally, Royal Bank Of Canada raised their price objective on shares of Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $659.25.

Get Our Latest Research Report on PRAX

Praxis Precision Medicines Trading Up 1.9%

NASDAQ PRAX opened at $310.90 on Friday. Praxis Precision Medicines has a 12-month low of $160.11 and a 12-month high of $392.70. The company has a market cap of $8.69 billion, a P/E ratio of -24.29 and a beta of 2.85. The company has a fifty day simple moving average of $286.77 and a 200 day simple moving average of $314.30.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.54) by $0.31. Sell-side analysts predict that Praxis Precision Medicines will post -13.72 EPS for the current year.

Institutional Investors Weigh In On Praxis Precision Medicines

Several institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in shares of Praxis Precision Medicines by 6.8% during the 1st quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock valued at $1,113,514,000 after buying an additional 218,777 shares during the last quarter. Perceptive Advisors LLC increased its holdings in shares of Praxis Precision Medicines by 2.0% during the first quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company’s stock valued at $655,974,000 after purchasing an additional 40,000 shares during the period. Bank of America Corp DE lifted its position in Praxis Precision Medicines by 2.3% in the first quarter. Bank of America Corp DE now owns 534,604 shares of the company’s stock worth $172,244,000 after purchasing an additional 11,841 shares during the period. Logos Global Management LP boosted its holdings in Praxis Precision Medicines by 63.5% during the third quarter. Logos Global Management LP now owns 425,000 shares of the company’s stock worth $123,773,000 after buying an additional 165,000 shares in the last quarter. Finally, Vivo Capital LLC raised its holdings in Praxis Precision Medicines by 3.0% during the 1st quarter. Vivo Capital LLC now owns 338,895 shares of the company’s stock worth $109,189,000 after buying an additional 10,000 shares during the period. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Recommended Stories

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.